GLPwatch
Papers (10410)
Page 142 of 174, ranked by citation count.
- Subclinical Changes in Type 2 Diabetes Patients with Heart Failure Stage A and B Treated with Oral Semaglutide.
- Diabetes with GLP-1R polymorphism (rs3765467) accompanied by myotonic dystrophy: A case of myotonic dystrophy with p.R131Q polymorphism at the glucagon-like peptide-1 receptor (rs3765467) resulting in marked effects of its agonist, dulaglutide.
- Greater time spent with HbA1c less than 7.0% with oral semaglutide versus oral comparators: An exploratory analysis of the PIONEER studies.
- Insulin degludec + liraglutide: a complementary combination.
- Efficacy and safety of once-weekly subcutaneous semaglutide 2.4 mg for the management of overweight or obesity in Asian populations: A systematic review, meta-analysis and meta-regression of randomised trials.
- Comparison of trajectories of self-monitored glucose levels by hypoglycemia status over 52 weeks of treatment with insulin glargine or exenatide once weekly.
- Cardiovascular Benefits of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Type 2 Diabetes Mellitus With Atherosclerotic Cardiovascular Disease: A Systematic Review of Randomized Controlled Trials.
- Comparison of the effects of exenatide and insulin glargine on right and left ventricular myocardial deformation as shown by 2D-speckle-tracking echocardiograms.
- US eligibility and preventable cardiovascular disease events from semaglutide in type 2 diabetes.
- Liraglutide prevents body and fat mass gain in ovariectomized Wistar rats.
- More on Semaglutide in Early Type 1 Diabetes.
- Knowledge, attitude and practice toward liraglutide and semaglutide among endocrinology medical staff.
- Effect of GLP-1 Receptor Agonists in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis.
- Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial.
- The Cardiac and Renal Safety of Semaglutide in Patients with Type 2 Diabetes: A Real-World Study Based on FAERS.
- The efficacy and safety of danuglipron and orforglipron in patients with type 2 diabetes and obesity: a systematic review and meta-analysis.
- Translating Guidelines into Practice: A Prospective Real-World Study of a Romanian Cohort Treated with GLP-1 RAs.
- High Dose of Liraglutide Impairs Renal Function in Female Hypertensive Rats.
- Glucagon-Like Peptide 1 Receptor Agonist Use and Vertebral Fracture Risk in Type 2 Diabetes.
- Case Report: Efficacy and safety of dose-escalated Mazdutide, a GLP-1/GCGR dual agonist, in an adolescent with obesity, type 2 diabetes, and hyperuricemia.
- Pharmacological management of type 2 diabetes mellitus in children and adolescents: A systematic review and network meta-analysis.
- Extended-release exenatide (Bydureon) for type 2 diabetes.
- 12-month outcomes of GLP - 1 in severe pediatric obesity: real-world data.
- The role of oral semaglutide in managing type 2 diabetes in Indian clinical settings: Addressing the unmet needs.
- Detection of adverse drug reactions among ordinary users of liraglutide on the occasion of drug dispensing in the community pharmacy setting.
- Table: GLP-1 and GIP/GLP-1 receptor agonists for chronic weight management.
- Breaking the mold: revolutionary new obesity drugs set to transform treatment landscape?
- Efficacy of tirzepatide versus semaglutide in achieving therapeutic targets in type 2 diabetes: a post hoc analysis of the SURPASS-2 Trial.
- Bridging the Gap to Waitlist Activation: Semaglutide's Weight Loss Efficacy and Safety in Patients With Obesity on Dialysis Seeking Kidney Transplantation.
- Semaglutide and Cardiovascular Outcomes.
- Liraglutide for patients with non-alcoholic steatohepatitis.
- Semaglutide Overdose in a Diabetic Patient: Suicidal Behavior and Multiorgan Failure.
- Recent diabetes issues affecting the primary care clinician.
- Semaglutide vs. dulaglutide for glycemic and weight control in patients with type 2 diabetes mellitus: A systematic review and meta‑analysis.
- Liraglutide Inhibits Autophagy to Ameliorate Post-Cardiac Arrest Brain Injury and Ferroptosis in Rats.
- Oral glucagon-like peptide-receptor agonists (GLP1RA) counseling: comparison with insulin counseling.
- Effects of glucagon-like peptide-1 receptor agonists on alcohol consumption: a systematic review and meta-analysis.
- Response To "Superior Cerebrovascular Outcomes with Tirzepatide Versus Semaglutide: A Call for Cautious Interpretation of Observational Data".
- Exploratory safety investigations in normal, freely moving Göttingen Minipigs using telemetry: Pharmacological validation.
- Effect of switching from dulaglutide to tirzepatide on blood glucose and renal function.
- Intranasal Human Recombinant Modified Glucagon-Like Peptide-1: High Antihyperglycemic Activity and Duration of Action in Mice.
- The effects of the GLP1 analog liraglutide on allodynia and motor coordination in peripheral neuropathy induced by a chemotherapeutic agent, cisplatin.
- Redefining peptide therapeutics with semaglutide.
- Trends and Disparities in Newer GLP1 Receptor Agonist Initiation among Real-World Adult Patients Eligible for Obesity Treatment.
- Influence of Hydrophobic Ion Pairing on Formulation Performance of Liraglutide in PLGA Microspheres.
- Predictors and Characteristics of Hair Loss Among Users of GLP-1 Receptor Agonists: A Cross-Sectional Analysis.
- Kidney outcomes are altered by preconception weight modulation in rodent mothers with obesity.
- Predictive factors of response to liraglutide in patients with type 2 diabetes mellitus and metabolic syndrome.
- Liraglutide-Conjugated Poly(methyl vinyl ether-<i>alt</i>-maleic acid)-Coated Core-Shell Upconversion Nanoparticles for Theranostics of Diabetes.
- Short- and long-acting GLP-1 receptor agonists decrease female sexual behaviors in experienced rodents.
- Super response to liraglutide in people with obesity: A case report and literature review.
- Pharmacologic Treatment of Obesity in the Context of Type 2 Diabetes.
- Liraglutide and empagliflozin alleviate diabetic cardiomyopathy by reducing oxidative stress and inflammation.
- Glucose Control and Continuous Glucose Monitoring Metrics During 12 Months of Treatment with Tirzepatide in Overweight or Obese Patients with Type 1 Diabetes.
- Tirzepatide versus SGLT2 inhibitors for MASLD: a multi-institutional propensity score-matched cohort study.
- [Changes in weight, body composition, metabolic parameters and vitamin D in subjects with grade 3 and 4 obesity treated with liraglutide 3 mg].
- Gastrointestinal Symptoms in Obesity Therapy: Mechanisms, Epidemiology, and Management Strategies.
- [Efficacy of treatment with glucagon-like peptide receptor agonists-1 in Asian patients with type 2 diabetes mellitus].
- Comparison of Exendin-4 and Its Single Amino Acid Substitutions as Parent Peptides for GLP-1 Receptor Imaging Probes.
- Weight regain after bariatric surgery: A framework for management.